Background
==========

Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) characterized by myelin loss, varying degrees of axonal pathology and progressive neurological dysfunction \[[@B1]\]. Autoimmune mechanisms are thought to have major roles in the pathogenesis of MS \[[@B2]\] but the cause of the disease is not yet conclusively understood \[[@B1]\]. A maternal parent-of-origin effect in MS \[[@B3],[@B4]\] has now been well demonstrated but the biological basis underlying this remains unknown \[[@B5]\].

Approximately 3% of babies born in North America have a congenital anomaly \[[@B6]\]. A congenital anomaly is an abnormality of structure, function or body metabolism that is present at birth and results in physical or mental disability, with varying degrees of severity \[[@B7]\]. Purely genetic factors (chromosomes, single gene mutations) are believed to account for 15-25% of all congenital anomalies leaving up to 80% due to multifactorial inheritance or environmental exposures \[[@B6]\]. These latter two categories may be affected by factors such as fetal exposures to infection (e.g. cytomegalovirus, varicella, rubella), toxins (e.g. alcohol, cocaine, accutane) or maternal medical conditions (diabetes, epilepsy, phenylketonuria) \[[@B6]\]. It is possible that a compromised intrauterine environment underlies the maternal effect seen in MS. One hypothesis is that an abnormal intrauterine milieu leading to impaired fetal development could plausibly also result in increased susceptibility to MS. A possible marker for this intrauterine insult is the presence of a \"non-fatal\" congenital anomaly (hereafter referred to simply as a \"congenital anomaly\"). If this were true, one would expect an excess of congenital anomalies in MS patients compared to gender and ethnicity-matched controls.

Methods
=======

The population-based Canadian Collaborative Project on Genetic Susceptibility to Multiple Sclerosis (CCPGSMS) has been collecting perinatal data on MS index cases and spousal controls using structured telephone interviews with appropriate consents \[[@B7]\]. Data specific for the question of congenital anomalies were collected from mothers of index cases and mothers of controls. Each participating CCPGSMS site has obtained ethical approval from the relevant institutional review board. The entire project was reviewed and approved by the University of British Columbia in compliance with the Helsinki Declaration.

Statistical analyses
--------------------

The Chi squared test was used to assess significance when comparing the frequency of congenital anomalies in index cases and controls. The effect of congenital anomalies and sex on the risk of MS was assessed by logistic regression using the R statistical package.

Results
=======

Maternal information on congenital anomalies could be collected for 7063 MS index cases and 2655 spousal controls. The clinical and demographic details of the index cases and controls are shown in Table [1](#T1){ref-type="table"}.

###### 

Clinical and demographic details of MS index cases and controls

                                 MS Index Cases   Spousal Controls
  ------------------------------ ---------------- ------------------
  **n**                          7063             2655
                                                  
  **mean age in years (SD)**     50.2 (10.1)      52.3 (9.6)
                                                  
  **n (females)**                5319             807
                                                  
  **n (males)**                  1744             1848
                                                  
  **sex ratio (f:m)**            3:1              0.4:1
                                                  
  **% relapsing remitting MS**   82.3             /

SD = standard deviation, (f:m) = female to male sex ratio

Two hundred and seventy (3.8%) MS index cases reported a congenital anomaly, not significantly different (*p*= 0.97) from controls (n = 101, 3.8%). As there is a preponderance of females with MS \[[@B8]\], there is by definition a corresponding over-representation of male spousal controls. If the trait of interest is sex-limited, then analysis by sex stratified cases and controls is important \[[@B9]\]. When we compared male index cases and female controls separately from male index case and male controls, there were again no significant differences. Logistic regression confirmed this showing an effect of female sex on the risk of MS (*p*\< 1 × 10^-16^) but no effect of having a congenital abnormality (*p*= 0.92).

Discussion
==========

Environmental risk factors are known to be responsible for 8-12% of congenital anomalies and are a likely contributing factor in an additional 20-25% of anomalies as part of multifactorial inheritance \[[@B10],[@B11]\] If the same risk factors acting *in utero*contribute to both congenital anomalies *and*future MS risk, then congenital anomalies could be used as biomarkers for MS. The large MS index case and control sample size used in this study did not support this hypothesis. It may well be possible that congenital anomalies are not good markers for intrauterine risk factors specific to MS or that the effect is too small to observe, given that only a small proportion of anomalies are attributed solely to environmental factors.

Our study does have limitations. Maternal recall of congenital anomalies is likely influenced by the time elapsed from the child\'s birth and by the severity of the condition and may not be as reliable as clinical records. For example, a mother would more likely recall a congenital anomaly needing medical intervention (e.g. cleft lip or palate, talipes) than one that may not (e.g. minor cardiac septal defect, spina bifida occulta). Conversely, a mother may over-report minor afflictions as congenital anomalies or they may report anomalies not detected at birth. The latter would help to explain the relatively high rate of anomalies observed compared to expected rates. As part of the CCPGSMS to date, we did not ask specifically for information on the type and severity of the congenital abnormality, which maybe important for MS risk. We also did not ask about the maternal history of fatal congenital abnormalities in previous pregnancies; this information would be missing from the family history especially if an affected pregnancy resulted in a termination, miscarriage, stillbirth, or perinatal death. We anticipate conducting a more focused questionnaire interview in the future as part of the ongoing CCPGSMS.

Conclusions
===========

The maternal effect in MS is substantial. Risk for MS in maternal half-siblings compared with the risk for full siblings does not differ significantly indicating that maternal effects might even be the major component of familial aggregation of the disease \[[@B4]\]. Our data suggests that congenital anomalies are not more prevalent among those who develop MS and seems to reduce the likelihood that there is a strong association between risk factors common to MS and congenital anomalies. However our study is a preliminary investigation as we did not have detailed data on congenital anomalies or maternal birth history. Further investigations are needed to explain the mechanisms underlying the increased MS risk conferred maternally.
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